Stella Pharma Corporation
Execution of Investigator-Initiated Clinical Study Agreement Regarding 18F-FBPA Uptake in Deep-Seated Cancers
To advance BNCT development in deep-seated cancer indications, Stella Pharma Corporation has executed an investigator-initiated clinical study agreement with Fujita Health University and others. The study will explore 18F-FBPA uptake to obtain foundational data for potential future label expansion. Based on the status as of August 2026, the impact on the fiscal year ending March 2027 is expected to be minimal.
Key Figures
- Key figure 1: Unknown (impact on fiscal year ending March 2027 described as minimal)
- Key figure 2: Unknown (no specific contract amount or term disclosed)
- Key figure 3: Unknown (no disclosure of sales or profit items)
AI要約
Overview of Business and Research Collaboration
Stella Pharma Corporation is advancing R&D aimed at BNCT expansion into deep-seated cancer indications in collaboration with Fujita Health University, Atransen Technologies, Sumitomo Heavy Industries, and Micron. This study, announced as the execution of an investigator-initiated clinical study agreement, is an exploratory evaluation of 18F-FBPA uptake. As part of initiatives following a related memorandum of understanding dated 1994, the study will use 18F-FBPA PET to examine tumor accumulation characteristics of boron agents for BNCT.
Outlook and Impact
The agreement aims to accumulate foundational data for expansion into deep-seated cancer indications and may enable future BNCT label expansion. At this time, any direct impact on fiscal year 2027 performance is expected to be minimal, and the company intends to promote expansion into deep-seated cancer indications through the research collaboration.
Stella Pharma Corporation
Company overview · Stock price · Financial data · All IR
